{"id":52618,"date":"2026-04-21T06:28:10","date_gmt":"2026-04-21T06:28:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/52618\/"},"modified":"2026-04-21T06:28:10","modified_gmt":"2026-04-21T06:28:10","slug":"assessing-roche-holding-swxrog-valuation-after-new-c4-therapeutics-oncology-partnership","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/52618\/","title":{"rendered":"Assessing Roche Holding (SWX:ROG) Valuation After New C4 Therapeutics Oncology Partnership"},"content":{"rendered":"\n

Find winning stocks<\/a> in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.<\/p>\n

Roche Holding (SWX:ROG) shares are in focus after C4 Therapeutics announced a new collaboration to develop degrader antibody conjugates for oncology, combining targeted protein degradation with antibody drug conjugation.<\/p>\n

See our latest analysis for Roche Holding.<\/a><\/p>\n

Roche Holding’s share price has softened recently, with a 1 month share price return of 10.47% and a 7 day share price return of 3.04%. However, the 1 year total shareholder return stands at 10.30%, which hints that long term momentum remains more constructive than the short term swings around news like the C4 Therapeutics collaboration.<\/p>\n

If this kind of oncology partnership has your attention, it may be a good moment to scan for other healthcare names using advanced data tools such as 127 healthcare AI stocks<\/a><\/p>\n

With Roche trading at CHF 322.30, about 13% below the CHF 363.47 analyst target and with some models indicating a larger intrinsic discount, you have to ask: is this a genuine value gap, or is the market already pricing in future growth?<\/p>\n

According to the most followed narrative from Clive_Thompson, Roche Holding’s fair value of CHF 430.01 sits well above the last close at CHF 322.30. This puts the current price in clear focus for anyone tracking long term cash flow potential.<\/p>\n

Free Cash Flow (FCF): I project a base case FCF of CHF 11.5 billion for 2026, which is broadly in line with the 2025 actual of CHF 11.8 billion. I assume a conservative perpetual growth rate of 3.0% thereafter, reflecting the long-term growth potential of the pipeline.<\/p>\n

Read the complete narrative.<\/a><\/p>\n

Curious how steady free cash flow, a modest long term growth rate, and a relatively low discount rate combine to reach CHF 430.01? The narrative also layers on profit margins and earnings assumptions that might surprise you, especially when set against a mature pharma business with a long history of cash generation.<\/p>\n

Result: Fair Value of CHF430.01 (UNDERVALUED)<\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, you still need to weigh up clinical or regulatory setbacks in key trials, as well as future biosimilar competition to Perjeta and Tecentriq that could challenge this thesis.<\/p>\n

Find out about the key risks to this Roche Holding narrative.<\/a><\/p>\n

With mixed sentiment around Roche, it helps to act promptly, review the numbers for yourself, and weigh up the 5 key rewards and 1 important warning sign<\/p>\n

If Roche is on your radar, do not stop here. Use focused stock lists to spot other opportunities that match your style before the market moves on.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include ROG.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…\n","protected":false},"author":2,"featured_media":18683,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[962,134,994,842],"class_list":{"0":"post-52618","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-chf","9":"tag-roche","10":"tag-roche-holding","11":"tag-share-price"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116441285012043200","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/52618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=52618"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/52618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18683"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=52618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=52618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=52618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}